cinepazide
Sign in to saveAlso known as cinepazide maleate
Cinepazide or cinepazide maleate (Kelinao or Anjieli in China) is a vasodilator used in China for the treatment of cardiovascular and cerebrovascular diseases, and peripheral vascular diseases. It appears to work by potentiating A2 adenosine receptors.
Research
57 papers- Cinepazide maleate promotes recovery from spinal cord injury by inhibiting inflammation and prolonging neuronal survival.Drug development research · 2023
- [Effects of cinepazide maleate injection on blood pressure in patients with acute ischemic stroke and hypertension].Zhonghua nei ke za zhi · 2022
- Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis.Frontiers in pharmacology · 2024
- Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial.BMC neurology · 2020
- Cinepazide maleate protects PC12 cells against oxygen-glucose deprivation-induced injury.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014
via PubMed
Wikidata facts
- Mass
- 417.226
Show 5 more facts
- subject has role
- vasodilator agent
- chemical formula
- C₂₂H₃₁N₃O₅
- canonical SMILES
- COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCN(CC2)CC(=O)N3CCCC3
- isomeric SMILES
- COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)N2CCN(CC2)CC(=O)N3CCCC3
- Commons category
- Cinepazide
Sources (1)
via Wikidata · CC0
~3 min read
Encyclopedic overview
2 sectionsContents
- History
- References
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 447331147 | IUPAC_name = (2E)-1-{4-[2-Oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl}-3-(3,4,5-trimethoxyphenyl)-2-propen-1-one | image = Cinepazide.svg | image_class = skin-invert-image
| tradename = | pregnancy_AU = | pregnancy_US = | legal_AU = | legal_CA = | legal_UK = | legal_US =
Excerpted from Wikipedia’s “cinepazide” article, available under the CC BY-SA 4.0 licence.